SCHEMBL423848

SCHEMBL423848

CCOC(=O)c1cc(-c2ccc(F)c(C#N)c2)c(-c2cc(F)cc(Cl)c2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.52
S1PR1 P21453 1/20 0.37
FNTA P49354 2/20 0.37
FNTB P49356 2/20 0.37
ALDH1A1 P00352 7/20 0.37
KDM4E B2RXH2 5/20 0.37
HPGD P15428 5/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
KMT2A Q03164 3/20 0.35
LMNA P02545 1/20 0.35
OPRD1 P41143 1/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRM6 O15303 1/20 0.35
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421904 0.87 MAPK14 (0.56) MAPK14ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL422503 0.86 MAPK14 (0.48) MAPK14FNTAFNTBALDH1A1KDM4E
SCHEMBL2509882 0.85 S1PR1 (0.36) MAPK14S1PR1FNTAFNTBALDH1A1
SCHEMBL424139 0.85 MAPK14 (0.46) MAPK14S1PR1CNR2PTGDR2
SCHEMBL420399 0.84 MAPK14 (0.51) MAPK14FNTAFNTBALDH1A1KDM4E
SCHEMBL2506075 0.78 CNR2 (0.39) S1PR1CNR2PTGDR2
SCHEMBL421731 0.76 MAPK14 (0.46) MAPK14ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL27005480 0.76 PRKCZ (0.51) MAPK14FNTAFNTBOPRD1MAPT
SCHEMBL421766 0.75 MAPK14 (0.39) MAPK14CNR2PTGDR2
SCHEMBL3609166 0.74 MAPK14 (0.61) MAPK14FNTAFNTBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
EP-2376482-B1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2013-03-06 EP disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075962-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 MAPK14 2294/4885S1PR1 3848/4885FNTA 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.